Cytoreductive nephrectomy in metastatic renal cell carcinoma: The evolving role of surgery in the era of molecular targeted therapy

Current Opinion in Supportive and Palliative Care

Volumn 3, Issue 3, 2009, Pages 157-165

  Kwan, Kevin G ^a   Kapoor, Anil ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cytoreductive nephrectomy; Metastasis; Renal cell carcinoma; Targeted therapy

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; METHODOLOGY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PATHOLOGY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; NEPHRECTOMY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 74549211455     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32832e466b     Document Type: Article

References (81)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian cancer statistics 2008. Toronto, Canada; 2008.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
3. Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173:1853-1862.
4. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am 2003; 30:843-852.
5. Medical Research Council Collaborators. Interferon-α and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet 1999; 353:14-17.
6. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171:1071-1076.
7. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655-1659.
8. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2005:CD001425.
9. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978; 120:148-152.
10. Montie JE, Stewart BH, Straffon RA, et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 117:272- 275.
11. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993; 150:463-466.
12. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
13. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163:408-417.
14. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alpha-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11:1368-1375.
15. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alpha interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987; 5:286-291.
16. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154:35-40.
17. Rackley R, Novick A, Klein E, et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994; 152:1399-1403.
18. Wolf JS Jr, Aronson FR, Small EJ, et al. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol 1994; 55:7-13.
19. Bennett RT, Lerner SE, Taub HC, et al. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995; 154:32-34.
20. Franklin JR, Figlin R, Rauch J, et al. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol 1996; 14:230-236.
21. Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997; 158:1691-1695.
22. Walther MM, Yang JC, Pass HI, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997; 158:1675-1678.
23. Figlin RA, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158:740-745.
24. Levy DA, Swanson DA, Slaton JW, et al. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol 1998; 159:1168-1172.
25. Wood CG, Huber N, Madsen L. Clinical variables that predict survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol 2001; 165 (5 Suppl):184A.
26. Mosharafa A, Koch M, Shalhav A, et al. Nephrectomy for metastatic renal cell carcinoma: Indiana University experience. Urology 2003; 62:636-640.
27. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon-α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966-970.
28. Wunderlich H, Steiner T, Kosmehl H, et al. Increased transforming growth factor β-1 plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol Int 1998; 60:205-207.
29. Wagner JR, Walther MM, Linehan WM, et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999; 162:43-45.
30. Sella A, Swanson DA, Ro JY, et al. Surgery following response to interferonalpha- based therapy for residual renal cell carcinoma. J Urol 1993; 149:19- 22.
31. Freed SZ. Nephrectomy for renal cell carcinoma with metastases. Urology 1977; 9:613-616.
32. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 2007; 177:1978- 1984.
33. Sengupta S, Leibovich BC, Blute ML, et al. Surgery for metastatic renal cell cancer. World J Urol 2005; 23:155-160.
34. Mickisch GH, Mattes RH. Combination of surgery and immunotherapy in metastatic renal cell carcinoma. World J Urol 2005; 23:191-195.
35. Walther MM, Lyne JC, Libutti SK, Linehman WM. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 1999; 53:496-501.
36. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: the M.D. Anderson Cancer Center experience. Urology 2006; 68:528-532.
37. Simmons MN, Kaouk J, Gill IS, Fergany A. Laparoscopic radical nephrectomy with hilar lymph node dissection in patients with advanced renal cell carcinoma. Urology 2007; 70:43-46.
38. Pautler SE, Choyke PL, Phillips JL. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma: a feasibility study. J Urol 2001; 165 (5 Suppl):185A.
39. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
40. Mejean A, Roupret M, Larousserie F, et al. Is there a place for radical nephrectomy in the presence of metastatic collecting duct carcinoma? J Urol 2003; 169:1287-1290.
41. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174:1759-1763.
42. Leibovich BC, Han K, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Oncology 2003; 98:2566-2575.
43. Vaselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166:68-72.
44. Pantuck A, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer 2003; 97:2995.
45. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000; 34:246-251.
46. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal cell carcinoma. J Urol 1986; 136:376-379.
47. Fujikawa K, Matsui Y, Oka H, et al. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 1999; 162:1934-1937.
48. Lee SE, Byun SS, Han JH, et al. Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int 2006; 98:1228-1232.
49. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated system. J Clin Oncol 2001; 19:1649.
50. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging system. J Urol 2000; 163:1090-1095.
51. Shuch B, La Rochelle JC, Wu J. Performance status and cytoreductive nephrectomy. Redefining management in patients with poor performance. Cancer 2008; 113:324-331.
52. Margulis V, Wood CG. Is patient performance status always an accurate surrogate for predicting tumor biology in patients with metastatic renal cancer? Cancer 2008; 113:1282-1283.
53. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with nodenegative metastatic renal cell carcinoma. Urology 2003; 61:314-319.
54. Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for nonmetastatic renal cell carcinoma. BJU Int 2003; 92:901-905.
55. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63-67.
56. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:2395-2400.
57. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296.
58. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-841.
59. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110:543-550.
60. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1552- 1558. Nomogram to predict 12-month PFS for patients receiving sunitinib.
61. Kader AK, Tamboli P, Luongo T, et al. Cytoreductive nephrectomy in the elderly patient: the M.D. Anderson Cancer Center experience. J Urol 2007; 177:855-861. (Pubitemid 46216349)
62. Rabets JC, Kaouk J, Fergany A, et al. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 2005; 64:930- 934.
63. Eisenberg MS, Meng MV, Master VA, et al. Laparoscopic versus open cytoreductive nephrectomy in advanced renal cell carcinoma. J Endourol 2006; 20:504-508.
64. Hutterer GC, Patard JJ, Colombel M, et al. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer 2007; 110:2428-2433.
65. Krambeck AE, Leibovich BC, Lohse CM, et al. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol 2006; 176:1990- 1995; discussion 1995.
66. Kassouf W, Sanchez-Ortiz R, Tamboli P, et al. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology 2007; 69:835-838. (Pubitemid 46670221)
67. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356:125-134.
68. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
69. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
70. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
71. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
72. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
73. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet 2007; 370:2103-2111.
74. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918.
75. Van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 2008; 14:2431-2436.
76. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181:518-523; discussion 523. One of several upcoming trials demonstrating the use of targeted molecular therapy in the neoadjuvant setting.
77. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008; 180:94-98. Morbidity of a contemporary cohort of patients receiving current targeted molecular therapies.
78. Kim B, Louie AC. Surgical resection following interleukin-2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 1992; 127:1343.
79. Sherry RM, Pass HI, Rosenberg SA, Yang JC. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 1992; 69:1850.
80. Murthy SC, Kim K, Rice TW, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 2005; 79:996-1003.
81. Pfannschmidt J, Hoffmann H, Muley T, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002; 74:1653-1657.